APEC1621-G: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Vemurafenib in Patients with Tumors Harboring BRAF V600 Mutations

APEC1621G NCI-COG PEDIATRIC MATCH (MOLECULAR ANALYSIS FOR THERAPY CHOICE)- PHASE 2 SUBPROTOCOL OF VEMURAFENIB IN PATIENTS WITH TUMORS HARBORING BRAF V600 MUTATIONS GOALS AND OBJECTIVES (SCIENTIFIC AIMS) 1.1 Primary Aims To determine the objective response rate (ORR; complete response + partial response) in pediatric patients treated with vemurafenib with advanced solid tumors (including CNS tumors), lymphomas or histiocytic disorders that harbor activating BRAF V600 mutations. 1.2 Secondary Aims To estimate the progression free survival in pediatric patients treated with vemurafenib with advanced solid tumors (including CNS tumors), lymphomas or histiocytic disorders that harbor activating BRAF V600 mutations. To obtain information about the tolerability of vemurafenib in children with relapsed or refractory cancer. 1.3 Exploratory Aims To explore approaches to profiling changes in tumor genomics over time through evaluation of circulating tumor DNA.